Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders. by Pollak, Thomas A et al.
Rowan University 
Rowan Digital Works 
School of Osteopathic Medicine Faculty 
Scholarship School of Osteopathic Medicine 
1-1-2019 
Antibodies in the Diagnosis, Prognosis, and Prediction of 
Psychotic Disorders. 
Thomas A Pollak 
King's College London 
Jonathan P Rogers 
King's College London 
Robert G Nagele 
Rowan University 
Mark Peakman 
King's College London 
James M Stone 
King's College London 
See next page for additional authors 
Follow this and additional works at: https://rdw.rowan.edu/som_facpub 
 Part of the Biological Phenomena, Cell Phenomena, and Immunity Commons, Immunopathology 
Commons, Medical Immunology Commons, Neuroscience and Neurobiology Commons, and the 
Psychiatry Commons 
Let us know how access to this document benefits you - 
share your thoughts on our feedback form. 
Recommended Citation 
Pollak, Thomas A; Rogers, Jonathan P; Nagele, Robert G; Peakman, Mark; Stone, James M; David, Anthony 
S; and McGuire, Philip, "Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders." 
(2019). School of Osteopathic Medicine Faculty Scholarship. 142. 
https://rdw.rowan.edu/som_facpub/142 
This Article is brought to you for free and open access by the School of Osteopathic Medicine at Rowan Digital 
Works. It has been accepted for inclusion in School of Osteopathic Medicine Faculty Scholarship by an authorized 
administrator of Rowan Digital Works. For more information, please contact brush@rowan.edu. 
Authors 
Thomas A Pollak, Jonathan P Rogers, Robert G Nagele, Mark Peakman, James M Stone, Anthony S David, 
and Philip McGuire 
This article is available at Rowan Digital Works: https://rdw.rowan.edu/som_facpub/142 
233
Schizophrenia Bulletin vol. 45 no. 1 pp. 233–246, 2019 
doi:10.1093/schbul/sby021
Advance Access publication February 21, 2018
© The Author(s) 2018. Published by Oxford University Press on behalf  of the Maryland Psychiatric Research Center.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Antibodies in the Diagnosis, Prognosis, and Prediction of Psychotic Disorders
Thomas A. Pollak*,1,5, Jonathan P. Rogers1,5, Robert G. Nagele2, Mark Peakman3, James M. Stone4,  
Anthony S. David1, and Philip McGuire1
1Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK; 
2Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, 
NJ; 3Department of Immunobiology, Faculty of Life Sciences & Medicine, King’s College London, London, UK; 4Department of 
Neuroimaging, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, 
London, UK
5Joint first authors.
*To whom correspondence should be addressed; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, 
King’s Health Partners, King’s College London, De Crespigny Park, Denmark Hill, London SE5 8AF, UK; tel: +44 (0) 207-848-5135, 
fax: +44 (0) 207-848-0572, e-mail: thomas.pollak@kcl.ac.uk
Blood-based biomarker discovery for psychotic disorders 
has yet to impact upon routine clinical practice. In physical 
disorders antibodies have established roles as diagnostic, 
prognostic and predictive (theranostic) biomarkers, partic-
ularly in disorders thought to have a substantial autoim-
mune or infective aetiology. Two approaches to antibody 
biomarker identification are distinguished: a “top-down” 
approach, in which antibodies to specific antigens are 
sought based on the known function of the antigen and its 
putative role in the disorder, and emerging “bottom-up” or 
“omics” approaches that are agnostic as to the significance 
of any one antigen, using high-throughput arrays to iden-
tify distinctive components of the antibody repertoire. Here 
we review the evidence for antibodies (to self-antigens as 
well as infectious organism and dietary antigens) as bio-
markers of diagnosis, prognosis, and treatment response in 
psychotic disorders. Neuronal autoantibodies have current, 
and increasing, clinical utility in the diagnosis of organic 
or atypical psychosis syndromes. Antibodies to selected in-
fectious agents show some promise in predicting cognitive 
impairment and possibly other symptom domains (eg, sui-
cidality) within psychotic disorders. Finally, infectious anti-
bodies and neuronal and other autoantibodies have recently 
emerged as potential biomarkers of response to anti-infec-
tive therapies, immunotherapies, or other novel therapeutic 
strategies in psychotic disorders, and have a clear role in 
stratifying patients for future clinical trials. As in nonpsy-
chiatric disorders, combining biomarkers and large-scale 
use of “bottom-up” approaches to biomarker identification 
are likely to maximize the eventual clinical utility of anti-
body biomarkers in psychotic disorders.
Key words:  psychosis/schizophrenia/antibody/biomarker/
inflammation
Introduction
According to the World Health Organization, psychotic 
disorders are the eighth most significant cause of global 
disability-adjusted life years among 15- to 44-year-olds, 
ranking above violence, hearing loss, and war.1 As well as 
the substantial loss of quality of life in schizophrenia, it 
is increasingly recognized that individuals with psychotic 
disorders have a reduced life expectancy, with one sys-
tematic review noting a standardized mortality ratio of 
2.58.2 These disorders also place an enormous burden on 
relatives and carers.3
Clinical medicine is entering an era in which there is 
an ever-greater emphasis on the early identification and 
prevention of disease4 and the development of personal-
ized treatment approaches.5 As such, biomarkers, which 
can be diagnostic, prognostic, or predictive, are currently 
being researched extensively across every area of medi-
cine and psychotic disorders like schizophrenia are no ex-
ception. A fundamental problem in the management of 
psychosis is that outcomes are not predictable on clinical 
grounds. For example, it is not possible to predict which 
individuals with prodromal symptoms will develop psy-
chosis, or whether a patient with psychosis will respond 
to conventional treatment.6–8 Hitherto, approaches to-
ward identifying biomarkers have included postmortem 
studies, structural and functional neuroimaging, prote-
omics, transcriptomics, metabolomics, and epigenetics. 
However, these methods have been plagued by small 
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effect sizes, population heterogeneity, and a consequent 
need for very large samples.9
Immune biomarkers are now used widely in relation 
to physical disease, both systemic and CNS-restricted, 
to improve clinical understanding and management, re-
flecting an increasing awareness of the involvement of 
the immune response in aspects of many diseases. With 
the recognition that psychotic disorders, too, have con-
siderable immune involvement, it is likely that immune 
biomarkers will play a role in the biological psychiatry of 
the future. Here we review the evidence for antibodies as 
diagnostic, prognostic, and predictive biomarkers in psy-
chotic disorders (table 1).
Immune and Inflammatory Mechanisms are Implicated 
in Psychotic Disorders
Autoimmune diseases occur when tissue destruction is 
mediated by self-antigen directed antibodies or T-cells.10 
To the extent that we understand the pathogenesis of 
psychotic disorders, there is insufficient evidence to 
claim that they are autoimmune in origin.11 There is, 
however, a consensus that psychotic disorders are het-
erogeneous, in many cases with complex multifactorial 
aetiologies. Some authors have proposed the categories 
of “primary” or idiopathic, and secondary psychoses, 
that is, those in which there is a clearly identifiable “or-
ganic” cause (eg, temporal lobe epilepsy, the 22q11 dele-
tion syndrome).12 Other authors have gone further still, 
arguing that the term “schizophrenia” should be replaced 
with a broader concept such as “psychosis spectrum dis-
order.”13 Nonetheless the evidence for some role for both 
adaptive and innate immune processes in the aetiology 
of some of these disorders continues to mount.14 Recent 
genome-wide association studies (GWAS) point toward 
immune-related loci in schizophrenia with multiple sus-
ceptibility genes identified on the major histocompati-
bility complex.15 When GWAS findings are grouped by 
known molecular pathways, several related to immunity 
and inflammation are implicated.16 Elevated serum levels 
of some inflammatory cytokines characterize the acute 
phase of psychotic disorders,17 and there is preliminary 
evidence that cytokines may have a role in predicting ill-
ness course or treatment response in individuals in the 
earliest stages of psychotic disorders.18,19
Prefiguring these more recent studies of inflammatory 
markers in psychotic disorders, associations between in-
fectious organisms and psychotic disorders have been 
described for over a century. Since the studies that linked 
an increased incidence of schizophrenia to epidemic in-
fluenza infection during the second trimester, associations 
have been noted between maternal exposure to influenza, 
Toxoplasma gondii and herpes simplex virus (HSV).20 In 
terms of later neurodevelopment, there is evidence that 
childhood and even adult infection with T.  gondii and 
other organisms is associated with psychosis.21–23
Epidemiological studies have also borne out the as-
sociation between psychotic disorders and autoimmune 
disease. Rates of autoimmune disorders such as celiac 
disease, Graves’ disease, systemic lupus erythematosus 
(SLE), multiple sclerosis, autoimmune hepatitis, and pso-
riasis are higher in those with schizophrenia.24 Moreover, 
a family history of multiple sclerosis, psoriasis, Sjögren’s 
Fig. 1. Two approaches to identification of antibodies for psychosis. The top-down approach is hypothesis-driven, based on candidate 
antigens identified from related disorders, genetic studies or putative neurobiology. The bottom-up approach is hypothesis-neutral 
and aims to identify predictive antibodies based on a large microarray. Both require validation with a cell-based assay (CBA) or other 
immunoassays such as enzyme-linked immunosorbent assay (ELISA).
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syndrome, dermatopolymyositis, or autoimmune hepa-
titis is associated with a greater risk of schizophrenia.24 
Severe infections and autoimmune diseases show inde-
pendent associations with schizophrenia, but they also 
have a synergistic effect on the risk.25
Focusing more specifically on humoral immunity, the 
notion that psychosis might be caused by a pathogenic 
antibody has a long history. A systematic review demon-
strated that among patients with established schizophre-
nia, 20 autoantibodies (including antinuclear antibody 
[ANA], anti-cardiolipin, anti-N-methyl-d-aspartate 
receptor [NMDAR], and anti-serotonin) were present 
at higher rates than among controls; rates of anticardio-
lipin and anti-NMDAR antibodies were also present in 
patients with first-episode psychosis.26 Even among the 
unaffected first-degree relatives of patients with schizo-
phrenia, a higher prevalence of some autoantibodies has 
been observed.26 However, the mere presence of an anti-
body does not imply pathogenicity.
Initially, associations with psychosis have been 
described for antibodies that reacted with entire brain 
regions.27 However, the reactivities of such antibodies are 
nonspecific enough that they are unlikely to be helpful 
in understanding pathogenesis or in distinguishing psy-
chotic disorders from other disorders. A  more refined 
hypothesis is that patients with psychotic disorders (or a 
subgroup thereof) have pathogenic antibodies against spe-
cific neuronal cell surface proteins such as the NMDAR, 
and research is ongoing to establish the aetiological and 
prognostic significance of this.28–30
Antibodies in the Prediction and Stratification of 
Physical Disease
Antibodies make suitable biomarkers for the pre-
diction of  disease because they are relatively eas-
ily measured in bodily fluids by a variety of  (usually 
inexpensive) immunoassays. Biomarkers—whether 
antibodies or otherwise—can have 3 distinct roles in 
medicine. They may be diagnostic, indicating the pres-
ence or absence of  a disease (although often their sen-
sitivity and specificity is such that they lend support to 
or help rule out a disease entity). They may be prog-
nostic, giving information on morbidity, mortality, or 
another outcome. Finally, they may be predictive, giv-
ing information on a patient’s likely response to spe-
cific treatments.31,32
Where a disorder has an established autoimmune basis, 
autoantibodies have a clear role as biomarkers, although 
crucially there is no requirement in any disease for an 
antibody to be pathogenic (causal) in order for it to have 
a useful biomarker role. Indeed, many of the biomark-
ers discussed here are unlikely to be causal. This concept 
may be the source of some confusion but is of utmost 
importance. To establish that an antibody is “causal” for 
a particular disease (ie, necessary and sufficient for the 
occurrence of disease) requires considerable evidential 
support in the fulfilment of the so-called Koch-Witebsky 
postulates, namely: (1) evidence of disease-specific adapt-
ive immune response in the affected target tissue, organ, 
or blood; (2) passive transfer of antibodies replicates the 
disease in experimental animals; and (3) elimination of 
antibodies modifies disease.10
If  an antibody is not primarily causal, it may still have 
an associated disease-modifying role and therefore shape 
phenotype despite not being required for the disease to 
be present. For example, circulating autoantibodies are 
the secreted product of a pathway that includes the gen-
eration of B lymphocytes bearing autoantibodies as their 
surface immunoglobulin. These are potent antigen-pre-
senting cells for autoreactive T cells and in this capacity 
alone are likely to drive immunopathology. Alternatively, 
antibodies may be raised in response to the primary dis-
ease pathology but may not be disease-causing in them-
selves (ie, “epiphenomenal”) or they may have an even 
less direct association with the disease pathology (eg, they 
may associate with a risk factor that in itself  is only con-
tributory to the disease). Whether or not an antibody is 
causal, therefore, is an independent question to that of 
its utility as a biomarker. If  an antibody is clearly causal 
then this may indicate that it will be a useful biomarker 
for clinical response to antibody-depleting immunothera-
pies, but there are many more useful contexts in which an 
antibody can have a useful biomarker role.
Most autoimmune diseases develop over a long period 
of time, with a period of subclinical autoreactive tissue 
damage before the development of overt symptoma-
tology. A paradigmatic example of the development of 
predictive antibody markers is that of type 1 diabetes 
(T1D). Based on seminal studies of first-degree relatives 
who were monitored for the development of T1D over 
15 years, the risk of developing the illness is now under-
stood to rise with the number of organ-specific autoan-
tibodies.33 Subsequent studies have refined the selection 
of at-risk individuals by using genetic criteria (HLA typ-
ing) and have provided robust risk estimates based on 
the “burden” of islet cell–specific autoantibodies. For 
example, children who develop two or more such auto-
antibodies have a risk of developing T1D in childhood or 
adolescence of >80%.34
In SLE, there are raised levels of  various autoanti-
bodies, including ANA, anti-dsDNA, ENA, anti-Ro, 
anti-La, anti-RNP, and anti-Sm.35 ANA is most com-
monly used as a “screening” test, wherein a positive 
result will prompt testing of  the other disease-associ-
ated antibodies. Patients with particular antibodies have 
an increased risk of  developing certain manifestations 
of  SLE.36 However, 4%–8% of  the healthy population 
(depending on the threshold used) are positive for ANA 
and rates are higher in those with multiple comorbidi-
ties, so it is not regarded as a specific test.37,38 Anti-
dsDNA is more specific, but this is at the expense of 
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sensitivity.37,38 Similar to T1D, autoantibodies have been 
shown to predate clinical manifestations in a large pro-
portion of  those who subsequently develop the disease 
with the lag time between seropositivity and diagnosis 
being as much as 9 years.39
Neuromyelitis optica (NMO) is a central nervous 
system disease characterized by inflammatory optical 
and spinal lesions. Previously characterized as “optical-
spinal” MS, the identification of pathogenic antibodies 
to the astrocytic water channel aquaporin-4 (AQP4)40 
heralded a recategorization of the disorder as an inde-
pendent entity.41,42 Specific antibody and B-cell depleting 
therapies have been shown to be efficacious and AQP4 
antibodies have been shown to predate the development 
of NMO. Furthermore, seropositivity at the time of an 
initial episode predicts higher relapse rates than sero-
negative status.41 Immunoglobulin access to the CNS 
is thought to be restricted by the blood-brain barrier 
(BBB). This suggests that the first step in pathogenesis, 
in NMO and other in autoantibody-mediated CNS dis-
eases, is BBB disruption: in the case of NMO due either 
to antibodies directed against AQP4 within the BBB43 
or to induction of IL-6 production by AQP4-positive 
astrocytes.44 This disruption may allow leakage of AQP4 
antibodies into the cerebrospinal fluid (CSF).45 We have 
reviewed the implications of BBB dysregulation in psy-
chosis elsewhere.46
Moving beyond antibodies targeting “self” antigens, 
antibodies to infectious organisms have also been useful 
as biomarkers in diseases not classically understood to 
be infectious. For instance, within oncology, Epstein-Barr 
Virus (EBV) is thought to have a causal role in the devel-
opment of Burkitt’s lymphoma and Hodgkin’s disease47; 
raised titers of antibodies to EBV are seen in both of 
these disorders.48 Similarly, antibodies to human papil-
loma virus may have a role in the prediction of outcomes 
for oropharyngeal squamous cell carcinomas.49
As well as being relevant in classically infectious and 
malignant disease, infectious organism antibodies are 
also thought to be implicated in autoimmune diseases. 
In Crohn’s disease, antimicrobial antibody serostatus 
(including to Saccharomyces cerevisiae) before diagno-
sis predicts subsequent disease course.50 The relation-
ship between infection, antibodies to infective pathogens, 
and autoimmunity is complex: a paradigmatic example 
is rheumatic fever, a disease that is precipitated by infec-
tion by Streptococcus pyogenes, a bacterium that usually 
produces an acute upper respiratory tract infection. In 
a minority, however, untreated infection with the path-
ogen results in subsequent weeks in inflammatory disease 
of the skin, joints, and myocardium. The mechanism 
thought to underlie this is known as molecular mimicry, 
whereby pathogens express antigens with similar epitopes 
to host tissue. This similarity is not sufficient to prevent 
an adaptive immunological response against the patho-
gen, but it does mean that once antibodies are formed, 
they can cross-react with host tissue.51 In rheumatic 
fever, antibodies produced against streptococcal anti-
gens cross-react with cardiac myosin, resulting in myo-
carditis.52 Other examples of autoimmune diseases that 
may have infective triggers are Graves’ disease (Yersinia 
enterocolitica mimics the TSH receptor) and multiple 
sclerosis (multiple viruses share epitopes with the mye-
lin basic protein).51 Apart from molecular mimicry, there 
are other proposed mechanisms to explain these associa-
tions: for instance, there may exist microbial “superanti-
gens” that could nonspecifically prime T-cells; bacterial 
endotoxins may cause polyclonal B-cell activation, or self  
antigen may undergo posttranslational modification to 
make it more immunogenic.53
The examples above largely feature antibodies that were 
specifically sought either within disease or at-risk cohorts, 
usually because of previous work demonstrating a plausi-
ble mechanistic link between the antigen in question and 
the disease state. This hypothesis-driven or “top-down” 
approach to biomarker validation has been successful to 
a point but, particularly in CNS disorders, has also high-
lighted an important cautionary lesson: that outside of 
strictly-defined autoimmune disease in which autoanti-
bodies are thought to be directly pathogenic, “classical” 
antigenic targets often miss their mark as the most use-
ful biomarkers.54 For example, serum autoantibodies to 
amyloid-β do not show a clear association with Alzheimer’s 
disease, and a similar lack of clarity characterizes the lit-
erature on α-synuclein antibodies in Parkinson’s disease.54
The last decade has seen the emergence of an alter-
native approach to the development of antibody-based 
diagnostic and predictive markers. High-throughput 
immunoassay platforms now allow for the simultane-
ous testing of antibodies to many thousands of anti-
genic targets on a single biological sample. This approach 
remains agnostic as to the potential significance of any 
one antigen in a given disease. It has been demonstrated 
that every individual harbors many thousands of autoan-
tibodies directed against self  antigens—so-called “natu-
ral autoantibodies”—and that the vast majority are not 
disease-causing. Indeed natural autoantibodies exist in 
multiple isotypes and with varying affinities in all indi-
viduals regardless of age, gender, or disease state, and the 
production of these autoantibodies is likely to represent a 
physiological “debris-clearing” response to tissue destruc-
tion or damage.55 It follows that the autoantibody profile 
of any individual might reflect any pathological process 
that is ongoing in that individual and can thus serve as a 
“readout” of the disease state in question (figure 1).
This approach is starting to be used with some success 
in neurodegenerative disorders.54 For example, using a 
panel of 50 autoantibodies, researchers were able to accu-
rately distinguish patients with mild cognitive impair-
ment from controls and from those with mild-moderate 
Alzheimer’s disease.56 Another study identified an auto-
antibody biomarker panel able to distinguish early-stage 
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Parkinson’s disease from disease and non-disease controls 
and showed promise for staging the disorder.57 A similar 
approach has shown some success in subtyping multi-
ple sclerosis.58 These studies provide hope for early diag-
nosis of neurodegenerative diseases using blood-based 
biomarkers without the need for expensive and invasive 
testing and with application in the primary care setting.
As was the case in genetics, where a genome-wide 
approach has supplanted a “top-down” single-gene 
approach, it is likely that a “bottom-up” approach to 
biomarker identification will prove particularly useful in 
complex disorders, with multifactorial aetiology, where 
pathology occurs in multiple systems. This is a model 
with increasing relevance to psychiatry, where simplistic 
“single receptor” or “single neurotransmitter” models of 
disease are in decline.
Special Considerations in Psychosis
Diagnostic Antibodies. Neuroimaging and blood-based 
biomarkers have thus far failed to completely distinguish 
psychotic from other psychiatric disorders.59–61 Given that 
there are no adequately sensitive and specific biomark-
ers for the diagnosis of primary or idiopathic psychotic 
disorders like schizophrenia, how could antibodies have 
any diagnostic role in the clinical assessment of patients 
presenting with psychosis?
One very clear use is in the diagnosis of a so-called 
organic (or “secondary”) psychotic disorders, which esti-
mates suggest may account for between 3% and 6% of all 
cases of psychosis.62,63 In the last decade, an increasing 
awareness of autoimmune encephalitis as a differential 
diagnosis of acute psychosis has led to many clinicians 
testing for neuronal autoantibodies as part of the initial 
assessment of patients presenting with a first episode of 
psychosis or even an acute relapse. The rationale is that 
early testing might point clinicians toward identifying 
an immunotherapy-responsive encephalopathy before 
neurological symptoms develop.64,65 It is notable in this 
regard that in the initial series of NMDAR encepha-
litis, nearly 80% of patients presented initially to men-
tal health services.66 Further, it is now understood that 
autoimmune encephalitides can also present monosymp-
tomatically, with only psychiatric symptoms but not neu-
rological symptoms.64,67,68 In much the same way that an 
autoantibody test (for aquaporin 4 antibodies) allowed 
neurologists to delineate and recategorize (as NMO) a 
small subgroup of patients with demyelinating disease 
that were previously subsumed under the broad category 
of MS,42 testing for NMDAR encephalitis may there-
fore allow psychiatrists to recategorize a proportion of 
cases that hitherto were subsumed under the category of 
“schizophrenia.”
In these cases, according to recent diagnostic consensus 
criteria, antibodies must be present in CSF or there must 
be other paraclinical evidence suggestive of encephalitis, 
such as electroencephalography (EEG), neuroimaging, or 
inflammatory CSF abnormalities.69 Therefore, antibody 
testing cannot in itself lead to a diagnostic recategoriza-
tion in a patient who presents with psychosis without 
additional symptoms, but it can guide further diagnostic 
investigation.
This approach does, therefore, leave a potentially large 
group of patients facing a lack of diagnostic clarity, that 
is, patients who present with psychotic symptoms and 
who have a positive serum neuronal autoantibody test 
result but who do not have EEG, neuroimaging, or CSF 
abnormalities. These patients have been designated “syn-
aptic and neuronal autoantibody-associated psychiatric 
syndromes” (SNAps) by Al-Diwani et  al70 and will be 
considered in section 3.3.
Other diagnoses of organic psychosis that can be aided 
by a positive antibody test are most often made in the 
context of a systemic or CNS disease that can present 
with psychosis. Examples include SLE, the antiphos-
pholipid syndrome, vasculitis, or neurosyphilis. In these 
cases, the diagnostic antibody is not usually specific to a 
psychotic presentation but to the disease more generally. 
One possible exception is psychosis associated with SLE 
(or “lupus psychosis”), which may be specifically associ-
ated with antibodies to the NR2 subunit of the NMDAR 
(and shown to cross-react with dsDNA) or with riboso-
mal P antibodies.71
Perhaps surprisingly, antibody-based diagnostics in 
psychiatry have probably impacted clinical practice most 
within the pediatric sphere. Pediatric acute-onset neu-
ropsychiatric syndrome (PANS) is a (somewhat conten-
tious) clinical diagnosis defined by the sudden onset of 
obsessive-compulsive symptoms or eating restrictions in 
combination with a number of other possible comorbid 
neuropsychiatric symptoms, and is strongly associated 
with infection with group A  streptococcus and other 
pathogens. Particularly relevant to this review, about a 
quarter of patients also present with psychotic symp-
toms, although these do not form part of the diagnostic 
criteria.72 PANS, along with a related syndrome, pediatric 
autoimmune neuropsychiatric disorder associated with 
streptococcal infections (PANDAS), have been variously 
associated with (putatively causal) antibodies target-
ing the basal ganglia, the dopamine D1 and D2 recep-
tors, enolase, beta-tubulin, and lysoganglioside-GM1 
(lyso-GM1).73 The sensitivity and specificity of various 
antibody-based diagnostics for these disorders is how-
ever variable, with a recent study demonstrating that a 
popular commercially available panel of antibodies (the 
Cunningham panel) had relatively poor performance 
in identifying children with clinically defined PANS/
PANDAS, with positive results among healthy controls 
and poor test-retest reliability.72
We suggest that a “bottom-up,” single-platform multi-
specificity detection approach may show promise in iden-
tifying diagnostic biomarkers for psychotic disorders, 
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although to what extent this is possible is of course likely 
to be dependent on the extent to which the psychotic dis-
order group is aetiologically heterogenous. By identifying 
the panel of  antibodies that most discriminate patients 
with psychotic disorder from matched healthy or psy-
chiatric controls, it is possible that truly diagnostic bio-
marker identification can be facilitated.
Prognostic Antibodies. A  fundamental challenge in 
the management of patients with psychosis is that the 
course of the disorder is remarkably heterogenous. Some 
patients have a single episode of psychosis and then make 
a very good recovery, with no further episodes of illness. 
Others have an episodic course, with successive periods of 
acute illness and remission. A further subgroup follows a 
chronic, unremitting course, with a progressive decline in 
functioning.74,75 These different types of patients require 
very different types and levels of clinical care. At the 
onset of illness, it is not possible, on the basis of their 
presenting clinical features, to predict which particular 
course a patient will follow. There is thus great interest in 
the potential of biomarkers to help stratify patients with 
psychosis according to their future clinical course.6
Additionally, there is mounting interest in biomarkers 
of particular domains of impairment in psychotic ill-
nesses; for example, cognitive dysfunction is recognized 
as an important predictor of outcome in psychosis, and 
indeed one that is relatively refractory to pharmacother-
apy.76 As “psychosis” is reconceptualized in the coming 
decades, it may become apparent that there is a subtype 
characterized by a progressive course and poor cognitive 
profile. In this sense, today’s prognostic biomarkers may 
have a diagnostic role in future practice.
Although neuronal autoantibodies, in the context of 
autoimmune encephalitis, have been linked with poor 
cognition and functioning over a follow-up period of 
years,77,78 their prognostic role in psychotic disorders has 
not been assessed.
A significant body of work has associated cogni-
tive deficits in psychosis with antibodies to viruses and 
other neurotropic pathogens, with the most commonly 
implicated organisms being HSV-1,79–82 cytomegalovi-
rus (CMV),83,84 and toxoplasma.81,85 Similarly, mortality 
from natural causes in schizophrenia is associated with 
antibodies to HSV-1, toxoplasma, and EBV.86,87 Finally, 
suicidality and a history of suicide attempts may be pre-
dicted by both the presence and titer of antibodies to 
CMV and toxoplasma.88–90
However, given the relatively high seroprevalences of 
antibodies to some of these pathogens, and the often 
small effect sizes in relation to the outcomes of interest, 
the possibility of confounding is high and it is unlikely 
that a single positive infective antibody test will have suf-
ficient clinical utility to inform management. A  related 
concern with the use infective antibodies as biomarkers 
is the extent to which the association with the outcome 
of interest is due to confounding with ethnicity, socioeco-
nomic status or other potentially relevant environmental 
factors such as urbanicity, migration status or lifestyle, 
and behavior.91–93
Finally, an unbiased “bottom-up” approach has 
recently been used for identification of prognostic auto-
antibodies in first episode psychosis: Zandian et al used 
microarrays to profile the autoantibody repertoire of first 
episode psychosis patients and controls. One of the most 
discriminant autoantibodies, targeting the N-terminal 
domain of the PAGE (P antigen) protein group, was 
linked to a 4-fold risk of future diagnosis of schizophre-
nia. Despite PAGE being a protein that had not previ-
ously been associated with psychosis, this pilot study is 
the first to employ a bottom-up approach for antibody 
biomarker identification in psychotic disorders, suggest-
ing clear promise for the general approach, and identify-
ing candidate biomarkers that would not have emerged 
from a hypothesis-driven, top-down approach.94
We suggest that a fruitful approach would be the identi-
fication of prognostic antibody biomarkers in subjects at 
clinical risk for psychosis. These individuals have “atten-
uated” psychotic symptoms, and about a third will prog-
ress to frank psychosis within 2 years.95 To date, no study 
has measured neuronal autoantibodies in this group to 
establish whether they predate the onset of frank psycho-
sis, and whether they confer risk for the subsequent devel-
opment of a psychotic disorder.
Predictive (Theranostic) Antibodies.  A final application 
for measurement of antibodies in patients with psycho-
sis is to predict response to treatment with antipsychotic 
medication. In this regard, it is too narrow to consider 
only the prediction of a positive response (ie, reduction 
of psychotic symptoms).8 Identification of predictors of 
treatment resistance or of adverse treatment effects is also 
a priority, as is identification of predictors of response 
to novel therapies such as immunotherapies. Finally, 
improvement in symptom domains other than explicitly 
psychotic symptoms, for example, cognitive deficits, is an 
important outcome to consider.
Considering the potential predictive role of  neu-
ronal autoantibodies, favorable outcomes have been 
reported when combinations of  corticosteroids, plas-
mapheresis, IVIg, mycophenolate mofetil, or rituximab 
have been used in a case series in patients with anti-
bodies to the NMDA receptor and no overt neurolog-
ical signs (ie, patients who do not have autoimmune 
encephalitis but who would meet Al-Diwani et  al’s 
“SNAps” definition70).96 Randomized trials of  immu-
notherapy in patients with psychosis and NMDAR and 
other neuronal autoantibodies are currently ongoing. 
If  positive, and a serum NMDAR antibody test can 
predict a good immunotherapy-response, the implica-
tions for clinical psychiatric practice are potentially 
transformative.
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(NMDAR antibodies have been shown to disrupt neu-
ronal glutamatergic signaling.97 It is possible that when 
detected in individuals with psychosis, then, these indi-
viduals may have a primarily glutamatergic rather than 
dopaminergic pathology. Furthermore, response to anti-
psychotic treatment in psychosis is associated with dopa-
minergic pathology and nonresponse with glutamatergic 
pathology.98,99 However, no study to date has assessed 
glutamatergic and/or dopaminergic function in NMDAR 
antibody–positive patients with psychosis.)
Interestingly there is some evidence that neuronal 
autoantibodies may be most frequently identified in sub-
groups of patients with psychosis that have classically 
been felt to be more “organic” in nature, for example, 
childhood-onset psychosis,100 postpartum psychosis,101 
or psychosis associated with epilepsy.102 These studies 
did not specifically assess immunotherapy-response. In 
the epilepsy literature, there is evidence that the presence 
of neuronal autoantibodies in chronic refractory “idio-
pathic” epilepsies indicates an increased likelihood of 
preferential response to immunotherapies over standard 
antiepileptic medications,103 raising the intriguing paral-
lel possibility that neuronal autoantibody status in these 
psychoses may index immunotherapy-responsiveness 
over antipsychotic-responsiveness.
Further, NMDAR antibodies may indicate that a 
patient will have an adverse response to antipsychotic 
medications, with increased rates reported of rhabdomy-
olysis and neuroleptic-malignant syndrome-type reac-
tions as well as extrapyramidal symptoms.104,105
Where autoantibodies to specific receptors indi-
cate dysfunction of the associated neurochemical sys-
tem, these antibodies may represent an opportunity for 
treatments targeting that system. For example, folate 
receptor antibodies were described in 15 of 18 patients 
(83.3%) with refractory schizophrenia, compared with 
3.3% of healthy controls. These antibodies were hypoth-
esized to block the receptor and modulate flux of folic 
acid into and out of the brain in a manner analogous 
to that seen in infantile-onset cerebral folate deficiency 
syndrome. Eight seropositive patients were treated with 
folinic acid supplementation with improvement reported 
in 7 patients.106 No randomized study has yet attempted 
to replicate this interesting open-label study. In a simi-
lar vein, a single case study demonstrating improvement 
in psychotic symptoms in a woman with chronic schiz-
ophrenia, NMDAR antibodies and characteristic EEG 
abnormalities reported significant improvement with 
d-serine, an NMDAR co-agonist.107
Hashimoto’s encephalopathy (also known as steroid-
responsive encephalopathy associated with autoimmune 
thyroiditis, SREAT) is characterized by diverse neuropsy-
chiatric signs in the presence of thyroid autoantibodies.108 
Symptoms cannot merely be attributed to thyroid dys-
function.109 Endres et al110 have recently reported a case of 
elevated antithyroid peroxidase (TPO) antibody levels in 
a patient with a schizophrenia-like illness who responded 
well to immunosuppression with corticosteroids. They 
also reported antibodies to either TPO or thyroglobulin 
(TG) in 13 of a series of 100 patients with schizophreni-
form syndromes,111 raising the possibility that TPO and 
TG antibodies could be used to characterize a group of 
patients who might respond well to corticosteroid therapy.
Antibodies to infectious antigens may have a special 
role in personalizing adjunctive treatment for patients 
with psychotic disorders. An open-label study in 2003 
showed an improvement in psychiatric symptoms in 
patients with schizophrenia who were seropositive for 
CMV,112 but this was not replicated in a randomized dou-
ble-blind trial.113 Prasad et al,114 in a placebo-controlled, 
double-blind randomized controlled trial (RCT) showed 
that 18 weeks of valacyclovir treatment improved cogni-
tion in a number of domains, but not psychotic symp-
toms, in HSV-1 seropositive patients with schizophrenia.
Despite the evidence of an association between psy-
chotic disorders and antibodies against toxoplasma, 
these antibodies do not appear to predict symptomatic 
response to anti-toxoplasma therapy in schizophrenia, 
insofar as 4 RCTs have failed to find a main effect on psy-
chotic symptoms.115 Notably one study did find that arte-
mether treatment was associated with a greater reduction 
in PANSS negative symptom scores, and in clinical global 
impression scores, when compared with placebo, in 100 
toxoplasma antibody–positive schizophrenia patients, 
although this was not the primary outcome of the trial.116
Recently, dietary antibodies have been implicated in the 
pathogenesis of some cases of psychotic disorder.117–120 
Case studies and case series indicate that patients who 
are seropositive for antibody markers of gluten sensitiv-
ity (eg, anti-gliadin, anti-transglutaminase antibodies)121 
may benefit symptomatically from gluten-free diets122–124 
although trial evidence is lacking.
Conclusions and Future Directions
The gold-standard biomarker is one that is highly sen-
sitive, highly specific and noninvasive.125 The biomarkers 
that we have surveyed in relation to psychosis do not cur-
rently meet standards that would support their general 
clinical use as biomarkers for diagnosis or prognostica-
tion of typical psychotic disorders, nor for predicting the 
response of psychotic symptoms to antipsychotic medi-
cation. However, there may be a promising role for anti-
bodies in the following situations:
1. diagnosis of organic or atypical psychosis syndromes;
2. clinical course in primary psychotic disorders, particu-
larly as regards cognitive impairment;
3. prediction of likelihood of response to immunother-
apy or other novel therapeutic strategies.
Regarding neuronal autoantibodies in particular, con-
siderable further work is required to evaluate their role 
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as biomarkers in psychotic disorders. For example, our 
current understanding of how antibody status varies over 
time is poor. For instance, antibody titers may go up and 
down, possibly in association with psychotic symptom 
severity. Further longitudinal studies, both of treatment-
naïve patients with established psychotic disorders and of  
patients at high clinical risk for the development of such 
disorders are required to assess the utility of autoanti-
body measurement in psychotic disorders.
Multiple antibodies have emerged as potential bio-
markers of response to atypical treatment strategies (eg, 
immunotherapies, anti-infective therapies, nutritional or 
dietary manipulations) in psychotic disorders. Generally, 
however, randomized controlled trial evidence is lacking 
or is inconclusive. What is clear is that these antibodies 
can be an essential part of future study design and strat-
ification of patients into treatment groups. Indeed, fail-
ure to stratify patients in this way to date may underlie 
the limited success of trials of some novel therapies (eg, 
immunotherapies) in psychotic disorders.
With regard to diagnosis, it is important to consider 
that psychiatric diagnoses lack pathological specificity. 
There is an emerging consensus that unlike, say, T1D, 
NMO or Alzheimer’s disease, “psychosis” denotes a het-
erogenous group of  disorders with likely diverse aetiolo-
gies. Some authors have seen psychiatric diagnoses as 
“manmade abstractions, liable to be discarded or modi-
fied,” 126 while others have argued that despite the multi-
plicity of  causes, there exists a “final common pathway” 
that results in the clinical expression of  psychosis.127 If  
we accept heterogeneity but also the likely existence of 
some common pathway, this has important implications 
for the development of  antibody-based biomarkers. It 
suggests that the “top-down”/single-antigen approach 
may be unsuccessful in identifying single biomarkers 
that are diagnostic of  a psychotic disorder. Where this 
approach is more likely to show utility is in the identifica-
tion of  disease subtypes and the consequent implications 
for treatment stratification. It may be that individual 
antibodies will be of  doubtful diagnostic, prognostic, or 
predictive significance alone, and that multiple antibod-
ies in combination will guide management. It is possi-
ble that this will lead to greater sensitivity and specificity 
although arguably at the expense of  a simple model of 
the pathophysiology.
Indeed, the possibility of a shared common mechan-
ism despite potentially varied aetiology suggests that a 
hypothesis-neutral, -omics approach (the “bottom-up” 
approach) may be an appropriate strategy for predictive 
biomarker identification going forward.
In parallel to the research outlined here on antibod-
ies as psychosis biomarkers, the emerging immunologi-
cal perspective on psychotic disorders has suggested that 
other classes of biomarker, such as cytokines, chemo-
kines, and even metagenomic indices of the microbiome 
may all have a role in bringing psychosis into the era of 
personalized medicine. How these measures might relate 
to antibody serostatus remains unclear although a com-
plex, interactive picture is beginning to emerge from other 
areas of medicine.128
Finally, experience from biomarker identification 
in other medical disorders has reinforced the value of 
approaches that combine multiple biomarkers with 
clinical and demographic data to maximize predictive 
potential.7,129,130 It is likely that where psychotic disor-
ders are concerned, too, the utility of  an individual’s 
antibody profile will be strengthened when used in 
combination with complementary, non-antibody-based 
prediction approaches, potentially incorporating neu-
roimaging, environmental, clinical, genomic, and pro-
teomic data.
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